Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2024 07:00 ET | Source: https://immatics.com/

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median...
January 17, 2024 20:30 ET | Source: https://immatics.com/

Immatics Announces Pricing of $175 Million Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
January 17, 2024 16:01 ET | Source: https://immatics.com/

Immatics Announces Proposed Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
November 14, 2023 07:00 ET | Source: https://immatics.com/

Immatics Announces Third Quarter 2023 Financial Results and Business Update

ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including...
November 08, 2023 07:00 ET | Source: https://immatics.com/

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for...
October 24, 2023 07:00 ET | Source: https://immatics.com/

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer typesRegulatory activities...
September 11, 2023 07:00 ET | Source: Immatics N.V.

Moderna und Immatics geben strategische Multi-Plattform-Kollaboration zur Entwicklung innovativer Onkologie Therapeutika bekannt

Kollaboration kombiniert führende Technologien zur Entwicklung bahnbrechender, in vivo exprimierter mRNA TCER®-MoleküleDie Unternehmen werden zur Entwicklung neuartiger Krebsimpfstoffe Immatics...
September 11, 2023 07:00 ET | Source: https://immatics.com/

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® moleculesCompanies to leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s...
August 17, 2023 07:00 ET | Source: Immatics N.V.

Immatics veröffentlicht Ergebnisse des zweiten Quartals 2023 sowie ein Update zur Geschäftsentwicklung

Klinische Phase-1/2-Studie zur Untersuchung von Immatics‘ zweitem bispezifischen TCR-Programm der nächsten Generation mit verlängerter Halbwertszeit, TCER® IMA402 (Zielstruktur: PRAME),...
August 17, 2023 07:00 ET | Source: https://immatics.com/

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME...